A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (the DRAW Study)
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Pharmacokinetics
- Acronyms DRAW
- 11 Jul 2017 Status changed from recruiting to completed.
- 26 Aug 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 26 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2018.